CD274 and neoplasm: In the Phase 1b KEYNOTE-028 trial, Alley and colleagues enrolled patients with PD-L1 ≥ 1%-positive MPM—defined by membranous PD-L1 expression in 1% or more of the tumor and associated inflammatory cells, or positive staining in the stroma.